ScholarIQanswers from OpenAlex & ORCID
Hervé Tilly
ResearcherPublications, citations & collaboration network
Hervé Tilly is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hervé Tilly have?
ScholarIQindexed works
Hervé Tilly has 807 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hervé Tilly have?
ScholarIQcitation count
Hervé Tilly has 45,405 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hervé Tilly?
ScholarIQh-index
Hervé Tilly has an h-index of 104 in OpenAlex.
What is the i10-index of Hervé Tilly?
ScholarIQi10-index
Hervé Tilly has an i10-index of 368 in OpenAlex.
What is the ORCID of Hervé Tilly?
ScholarIQorcid
The ORCID for Hervé Tilly is on the source record.
What is the OpenAlex record for Hervé Tilly?
ScholarIQopenalex
The OpenAlex for Hervé Tilly is on the source record.
What are the most-cited papers on Hervé Tilly?
ScholarIQmost cited works
Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).
Christian Gisselbrecht, Philippe Gaulard, Éric Lepage, Bertrand Coiffier, Josette Brière, Corinne Haïoun, Dominique Cazals‐Hatem, André Bosly, Luc Xerri, Hervé Tilly, Françoise Berger, Réda Bouhabdallah, J Diébold
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Franck Morschhauser, Nathan Fowler, Pierre Feugier, Réda Bouabdallah, Hervé Tilly, M. Lia Palomba, Christophe Fruchart, Edward N. Libby, Olivier Casasnovas, Ian W. Flinn, Corinne Haïoun, Hervé Maisonneuve, Loïc Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Nicolas Daguindau, Steven Le Gouill, Gian M. Pica, Alejandro Martı́n, Armando López‐Guillermo, Jean-François Larouche, Kiyoshi Ando, María Gomes da Silva, Marc André, Pierre Zachée, Laurie H. Sehn, Kensei Tobinai, Guillaume Cartron, David Liu, Jianming Wang, Luc Xerri, Gilles Salles
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, Sarit Assouline, Laurie H. Sehn, Ian W. Flinn, Manish R. Patel, Randeep Sangha, Anton Hagenbeek, Ranjana H. Advani, Hervé Tilly, Olivier Casasnovas, Oliver W. Press, Sreeni Yalamanchili, Robert S. Kahn, Randall Dere, Dan Lü, Surai Jones, Cheryl Jones, Yu-Waye Chu, Franck Morschhauser
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies
Judith Trotman, Stefano Luminari, Sami Boussetta, Annibale Versari, Jehan Dupuis, Christelle Tychyj, Luigi Marcheselli, Alina Berriolo-Riedinger, Antonella Franceschetto, Anne Julian, Fabien Ricard, Luca Guerra, Corinne Haïoun, Irène Biasoli, Hervé Tilly, Massimo Federico, Gilles Salles, Michel Meignan